Industry Supported Satellite Symposia

Industry Supported Satellite Symposia

SUNDAY, 5 JULY, 2020

Changing Course in MDD

Scientific Committee: E. Vieta, Spain & J. A Ramos-Quiroga, Spain
Chair: E. Vieta, Spain
Co-chair: D. Dudek, Poland

 13:15-14:45 Industry Symposium supported by Hall: Auditorium A (Plenary)
13:15-13:25 Welcome and introduction
E. Vieta, Spain
13:25-13:50 Challenging definitions and improving response in MDD
D. Dudek, Poland
13:50-14:15 New paradigms in the management of MDD
J.A Ramos-Quiroga, Spain
14:15-14:40 Future perspectives: potential of precision medicine
E. Vieta, Spain
14:40-14:45 Closing
D. Dudek, Poland

The different aspects of schizophrenia treatment

Chair: C.U Correll, Germany

 13:15-14:45 Industry Symposium supported by Hall: Roma
13:15-13:20 Welcome and introduction
C.U Correll, Germany
13:20-13:45 Addressing functioning in Schizophrenia: what do patients need in the different phases of the disease?
P. Falkai, Germany
13:45-14:10 Broad spectrum treatment: which needs in schizophrenia can cariprazine address?
C.U Correll, Germany
14:10-14.35 Patient functioning and cariprazine: from symptoms to performance
C.U Correll, Germany

Could it be ADHD?
Missed or misdiagnosis in adults

Chair: D. Manders, UK

 13:15-14:45 Industry Symposium supported by Hall: Madrid
13:15-13:20 Welcome
D. Manders, UK
13:20-13:35 ADHD and comorbid conditions – different or differential diagnoses?
P. Mason, UK
13:35-14:05 ADHD and comorbid mood disorders in adults
G. Mattingly, USA
14:05-14:40 Recognising, diagnosing and managing ADHD in adults with comorbid conditions: ‘top tips’ for clinical practice
Panel discussion and questions from delegates

Moderator: D. Manders, UK
Panelists: L. Borg Skoglund, Sweden
P. Mason, UK
G. Mattingly, USA
A. Young, UK
14:05-14:40 Closing comments
D. Manders, UK

MONDAY, 6 JULY 2020

What is the ultimate goal of MDD treatment?

Chair: Roger McIntyre, Canada

13:15-14:45 Industry Symposium supported by Hall: Madrid
13:15-13:20 Chair’s welcome
R. McIntyre, Canada
13:20-13:35 Growing clinical evidence for vortioxetine
N. Glozier, Australia
13:35-13:50 Better but not well: what does success look like?
M. Alsuwaidan, Kuwait
13:50-14.10 Resilience and MDD: what is the current evidence?
R. McIntyre, Canada
14:10-14:25 Optimising treatment: switch, titrate or augment?
A. Fagiolini, Italy
14:25-14:45 Discussion and Q&A
R. McIntyre, Canada

TUESDAY, 7 JULY 2020

Treatment Choices in Schizophrenia in the Era of Personalized Medicine

Chair: C. Arango, Spain

13:15-14:45 Industry Symposium supported by Hall: Madrid
13:15-13:45 The art of psychopharmacology in schizophrenia
M.A Riva, Italy
13:45-14:15 Ranking antipsychotics for efficacy and safety
C.U Correll, Germany
14:15-14:45 Dimensional treatment of schizophrenia in the real-world clinical practice: which antipsychotic for which patient
A. Fagiolini, Italy